Clinical Trials
7
Active:1
Completed:4
Trial Phases
3 Phases
Phase 1:1
Phase 2:3
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)β’ Click on a phase to view related trials
Phase 2
3 (42.9%)Phase 3
3 (42.9%)Phase 1
1 (14.3%)Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-10-29
- Target Recruit Count
- 60
- Registration Number
- NCT06040346
- Locations
- π°πͺ
Kisumu County Referral Hospital, Kisumu, Kenya
To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19
Phase 3
Completed
- Conditions
- Post-COVID-19
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2024-05-28
- Target Recruit Count
- 121
- Registration Number
- NCT05813587
- Locations
- π¨π³
First Affiliated Hospital of the Air Force Medical University, Xi'an, China
Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19
Phase 3
Withdrawn
- Conditions
- COVID-19
- Locations
- π¨π³
First Affiliated Hospital of the Air Force Medical University, Xi'an, China
Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19
Phase 3
Completed
- Conditions
- COVID-19
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2024-05-28
- Target Recruit Count
- 108
- Registration Number
- NCT05679479
- Locations
- π¨π³
First Affiliated Hospital of the Air Force Medical University, Xi'an, China
the Safety and Efficacy of Meplazumab in Patients With COVID-19
Phase 2
Completed
- Conditions
- Covid19
- Interventions
- Drug: Sterile normal saline (0.9%)
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2023-09-15
- Target Recruit Count
- 150
- Registration Number
- NCT05113784
- Locations
- π¨π³
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
π¨π³The Third People's Hospital Of Shenzhen, Shenzhen, China
- Prev
- 1
- 2
- Next
News
No news found